Mozart Therapeutics Presents Preclinical Data for MTX-101, a Novel Bispecific CD8 Treg Modulator for Treatment of Autoimmune Diseases, at American College of Rheumatology Convergence 2023

2023-11-13
PRNewswire
AACR会议
SEATTLE, Nov. 13, 2023 /PRNewswire/ -- Mozart Therapeutics, a leading developer of CD8 Treg Modulators for the treatment of autoimmune and inflammatory diseases, presented preclinical pharmacology and tolerability data for MTX-101,a CD8 Treg modulator at the annual meeting of the American College of Rheumatology being held at the San Diego Convention Center in San Diego, CA.
Presented findings demonstrate:
CD8 Treg are present in rheumatological autoimmune diseases and show decreased expression of functional proteins and reduced responsiveness to stimulation relative to healthy donor CD8 Treg
MTX-101 selectively binds CD8 Treg and enhances their killing of self-reactive CD4 T cells by blocking inhibitory KIR
Enhanced MTX-101 mediated CD8 Treg function prevents self-reactive CD4 T cell expansion and inflammation, without unwanted immune cell activation or increase of pro-inflammatory cytokines
In non-clinical safety studies, MTX-101 was well-tolerated at doses up to 50 mg/kg
Data collectively support the therapeutic potential of MTX-101 for the treatment of autoimmunity including rheumatological diseases
"These results are important because they show the therapeutic potential of MTX-101 and validate the ability MTX-101 to restore the functionality of CD8 Treg in autoimmune diseases and to reestablish immune balance," said Kristine Swiderek, PhD, Chief Scientific Officer at Mozart Therapeutics.
The poster "Pre-Clinical Characterization of MTX-101, a Novel Bispecific CD8 Treg Modulator with the Potential to Restore CD8 Treg Functions in Patients with Rheumatological Autoimmune Diseases" (Abstract #0089) can be accessed from the Mozart Therapeutics website.
About MTX-101
MTX-101 is a bispecific CD8 Treg Modulator targeting inhibitory KIR and CD8 expressed on regulatory CD8 T cells. This autoimmune checkpoint inhibitorautoimmune checkpoint inhibitor aims to restore regulatory CD8 T cell function, acting early in the autoimmune disease process to halt downstream inflammation and prevent the perpetuation of tissue destruction.
Mozart Therapeutics is focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, utilizing a novel approach to restoring immune system function by targeting the CD8 T regulatory network. The company is headquartered in Seattle, WA. For more information visit www.mozart-tx.com and follow the company on LinkedIn @Mozart-tx.
Media Contact:
Julie Rathbun
Rathbun Communications
[email protected]
206-769-9219
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。